Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
- Astellas: Slight Sales Decline in 1st Half due to Strong Yen, Domestic Sales Virtually Unchanged
November 5, 2012
- “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
- Shionogi Licenses Alzheimer’s Disease Treatment to Janssen Pharmaceuticals of US
November 2, 2012
- DSP’s 1st Half Sales Up Mere 0.4 % due to Stagnant Domestic Sales, Profits Show Double-Digit Increase
November 2, 2012
- Takeda’s 1st Half Operating Profits Down 48% due to M&A Costs
November 1, 2012
- FDA Accepts Supplemental NDAs for Latuda for Bipolar Depression: DSP
November 1, 2012
- Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
- EpiPen Marketing Approval Transferred to Pfizer from Mylan
November 1, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…